Clinical Trial Update: DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 study comparing DP303c to Trastuzumab Emtansine in patients with HER2-positive advanced breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DP303c (DP303c)
• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 3 | Status: RECRUITING